Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Tuberous Sclerosis × dactolisib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neuroectodermal Tumors, Primitive 2 Uterine Neoplasms 1 Tuberous Sclerosis 1 Perivascular Epithelioid Cell Neoplasms 1 Neuroendocrine Tumors 1 Endometrial Neoplasms 1 Carcinoma, Transitional Cell 1 Breast Neoplasms 1 Angiomyolipoma 1

Interventions

Sirolimus 6 Everolimus 4 ganaxolone 1 dactolisib 1 Vigabatrin 1 Propranolol 1 Aspirin 1 Anticonvulsants 1 2-chloro-4-(1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl)pyridine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01690871 2013-08-02

A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Metastatic or Unresectable Malignant PEComa

Novartis

Phase 2 Withdrawn

Tuberous Sclerosis, Angiomyolipoma, Perivascular Epithelioid Cell Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡